BOL is reportedly the only Israeli company to comply with international regulations and the first to obtain approval for exporting medical cannabis products, manufactured under strict conditions.
Astral Health, a specialist import and distribution company, brokered a strategic partnership with BOL, which is Israel’s largest and leading manufacturer of GMP (good manufacturing practice) certified medical cannabis products.
The import marks the start of a new era for the UK medical cannabis industry after a period of reliance on irregular and unreliable pharmaceutical grade product coming into Europe from Canada and antiquated systems bringing in product from the Netherlands. “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market,” BOL Pharma CEO Dr. Tamir Gedo said.
“The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector.
“Further opening of the market to exports will enable Israel to become a world leader in the coming years.”
This medical cannabis shipment will be used to treat patients in the UK with treatment-resistant epilepsy, and marks the first of many shipments the company will make over the coming months from Israel.
The shipment comes after changes led by the Israeli government in its resolution from January, enabling BOL to operate as a leading exporter of cannabis and its derivatives.
“These are exciting times which symbolise a true breakthrough for the Israeli medical cannabis market,” said Hagai Hillman, BOL Pharma’s founder.
He added that Israel is at the forefront of the life science industry throughout the western world in terms of regulation, research and product development, and quoted BOL’s ongoing “advanced clinical studies for various indications, including pain syndromes, oncology, orthopaedics, neurology, gynaecology, autism and paediatric diseases”.
“Harnessing the developing exports will allow us to continue benefiting children and severely ill patients around the world,” he said.
Cannabis Health is THE UK magazine covering cannabis medicine and wellbeing from every angle. It is affiliated with the Medical Cannabis Clinicians Society and lists campaigner Hannah Deacon, leading expert Professor Mike Barnes and prominent doctor Dani Gordon on our editorial panel.
For a limited time only, we are offering a free – absolutely no strings – annual subscription to the quarterly print title. You will receive four issues, delivered with discretion to your address – with no hidden fees or obligation to pay beyond that. To repeat, this is a 100% free promotion available to the first 100,000 sign-ups.
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- Cannabis more ‘advantageous’ than conventional sleep aids
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure